NASDAQ: EDSA
Edesa Biotech Inc Stock Forecast, Predictions & Price Target

Analyst price target for EDSA

Based on 2 analysts offering 12 month price targets for Edesa Biotech Inc

Min Forecast
$5.00+137.53%
Avg Forecast
$13.00+517.58%
Max Forecast
$21.00+897.62%

Should I buy or sell EDSA stock?

Based on 2 analysts offering ratings for Edesa Biotech Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EDSA stock forecasts and price targets.

EDSA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-27
lockedlocked$00.00+00.00%2025-03-13

1 of 1

Forecast return on equity

Is EDSA forecast to generate an efficient return?

Company
N/A
Industry
169.9%
Market
89.75%

Forecast return on assets

Is EDSA forecast to generate an efficient return on assets?

Company
N/A
Industry
44.64%

EDSA earnings per share forecast

What is EDSA's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.23
Avg 2 year Forecast
-$0.97
Avg 3 year Forecast
-$0.45

EDSA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EDSA$2.11$13.00+517.58%Buy
HOOK$1.21N/AN/A
SONN$4.64$20.00+331.03%Strong Buy
BIVI$8.05N/AN/A
SYBX$1.24N/AN/A

Edesa Biotech Stock Forecast FAQ

Is Edesa Biotech Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: EDSA) stock is to Buy EDSA stock.

Out of 2 analysts, 0 (0%) are recommending EDSA as a Strong Buy, 2 (100%) are recommending EDSA as a Buy, 0 (0%) are recommending EDSA as a Hold, 0 (0%) are recommending EDSA as a Sell, and 0 (0%) are recommending EDSA as a Strong Sell.

If you're new to stock investing, here's how to buy Edesa Biotech stock.

What is EDSA's earnings growth forecast for 2025-2027?

(NASDAQ: EDSA) Edesa Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.

Edesa Biotech's earnings in 2025 is -$5,837,964.On average, 2 Wall Street analysts forecast EDSA's earnings for 2025 to be -$8,637,894, with the lowest EDSA earnings forecast at -$9,059,255, and the highest EDSA earnings forecast at -$8,216,533. On average, 2 Wall Street analysts forecast EDSA's earnings for 2026 to be -$6,811,998, with the lowest EDSA earnings forecast at -$9,691,296, and the highest EDSA earnings forecast at -$3,932,700.

In 2027, EDSA is forecast to generate -$3,160,205 in earnings, with the lowest earnings forecast at -$3,160,205 and the highest earnings forecast at -$3,160,205.

What is EDSA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EDSA) forecast ROE is N/A, which is considered weak.

What is EDSA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year EDSA price target, the average EDSA price target is $13.00, with the highest EDSA stock price forecast at $21.00 and the lowest EDSA stock price forecast at $5.00.

On average, Wall Street analysts predict that Edesa Biotech's share price could reach $13.00 by Jun 27, 2026. The average Edesa Biotech stock price prediction forecasts a potential upside of 517.58% from the current EDSA share price of $2.11.

What is EDSA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EDSA) Edesa Biotech's current Earnings Per Share (EPS) is -$1.59. On average, analysts forecast that EDSA's EPS will be -$1.23 for 2025, with the lowest EPS forecast at -$1.29, and the highest EPS forecast at -$1.17. On average, analysts forecast that EDSA's EPS will be -$0.97 for 2026, with the lowest EPS forecast at -$1.38, and the highest EPS forecast at -$0.56. In 2027, EDSA's EPS is forecast to hit -$0.45 (min: -$0.45, max: -$0.45).

What is EDSA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EDSA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 44.64%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.